MedTrace Logo

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

NCT00842673 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2012-06-07

No results posted yet for this study

Summary

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.

Conditions

Interventions

DRUG

ST101

30 mg; administered once/day

DRUG

ST101

90 mg; administered once/day

DRUG

ST101

180 mg; administered once/day

DRUG

Placebo

placebo to match ST101 tablets

Sponsors & Collaborators

  • Sonexa Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842673 on ClinicalTrials.gov